On Wednesday Tocagen Inc. (NASDAQ:TOCA) stock rose 1.24% and closed at 0.65. The stock opened the session at $0.64 and touched its highest price point at $0.68. Its recent trading capacity is 201657 shares versus to its average trading volume of 477484 shares. The company’s stock’s lowest price point for the session stood at $0.63. TOCA traded as low as $ 0.53 in the past 52 weeks, and shares hit its peak level to $14.75.
On Nov. 6, 2019, Tocagen Inc. (NASDAQ:TOCA) a clinical-stage, cancer-selective gene therapy company, disclosed it will report its third quarter 2019 financial results and business progress on Tuesday, November 12, 2019, after the close of the U.S. financial markets.
Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer. Tocagen’s lead investigational product candidate, Toca 511 & Toca FC, is under evaluation in a Phase 2/3 trial for patients newly diagnosed with glioblastoma, sponsored by the NCI and conducted by NRG Oncology, and a Phase 1 trial in patients with non-muscle invasive bladder cancer. Tocagen is advancing preclinical programs from its versatile gene therapy platform that represents a new approach in cancer immunotherapy.
Julia Brown is a Master’s in Business Administration by education. After completing her post-graduation, Julia jumped the journalism bandwagon as a freelance journalist. Soon after that she landed a job of reporter and has been climbing the news industry ladder ever since to reach the post of editor. As an avid day trader, Julia is a master of technical analysis and writes tirelessly on how stocks are trading. She has extensive knowledge in technical analysis & Finance writing.
Email: [email protected]
Address: 10397 217th Place Northeast, Arlington, WA 98223 USA
Contact number: 425-353-5499